Bringing immunoglobulin knowledge up to date: how should we treat today? - sprookjes - yvandenbroek - TriplyDB

Bringing immunoglobulin knowledge up to date: how should we treat today?

Bringing immunoglobulin knowledge up to date: how should we treat today?

http://www.wikidata.org/entity/Q37901520

about

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.Immunoglobulin therapy for refractory Crohn's disease.Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.Immunoglobulin replacement therapy for primary immunodeficiencies.Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients.Broadening the translational immunology landscape.

P2860

Q36196688-C46DE0AB-41A7-4DC8-BEC2-8962D5B16413 Q37519134-CAFAAB25-792F-4D0F-9812-2122B75492BA Q38029244-CF78DDFB-F893-4DB3-A833-B8DF729AC837 Q38122120-0E862EFD-D43D-4FC6-A764-549E6DD87C5C Q38257643-E8691AFD-DDCA-4CD9-BF13-41DD36ACB4B2 Q41322794-500BDC90-2C62-4970-92AB-46F906BDE15E Q50777385-0D4C6CED-2994-4357-AA5D-CD451AB1C03A

P2860

Bringing immunoglobulin knowledge up to date: how should we treat today?

http://www.wikidata.org/entity/Q37901520

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 July 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bringing immunoglobulin knowledge up to date: how should we treat today?

@en

Bringing immunoglobulin knowledge up to date: how should we treat today?

@nl

type

label

Bringing immunoglobulin knowledge up to date: how should we treat today?

@en

Bringing immunoglobulin knowledge up to date: how should we treat today?

@nl

prefLabel

Bringing immunoglobulin knowledge up to date: how should we treat today?

@en

Bringing immunoglobulin knowledge up to date: how should we treat today?

@nl

P1433

Q37901520-175817A0-B75E-4AB8-A95A-73C05BB63719

P1476

Q37901520-E3713E3A-7607-4A47-997A-E2E5D667E535

P2093

Q37901520-24D3C71B-5F36-4BC1-B1F7-8AFE9D72D4DA

Q37901520-5A9520C6-EDAD-479D-9960-3A7F010C3B42

Q37901520-96A997CA-F3FB-4625-AC5F-CE0138DD0D74

Q37901520-B6A19E79-E273-4CE3-885B-0AABAE1B4A86

Q37901520-CD614907-6098-463F-813D-5520A23E08AA

P2860

Q37901520-062B3B4F-804E-418E-9017-9E29D95000A6

Q37901520-06C83888-AA74-4795-8A7B-6FD7CE0A9E3F

Q37901520-0B7A64B5-E7DB-4F8E-A46F-9F846A92160B

Q37901520-1355B8A3-AE2A-44D5-AAB3-5178D51CE07D

Q37901520-16834236-C79F-4BDF-ACD6-6991B8E0F652

Q37901520-1C866A89-0C1C-44CD-99B5-9802F6F56581

Q37901520-1E3331E4-61CB-41A4-8312-AAB3EC272A6F

Q37901520-28FE0EDF-5C60-4B3E-9AAC-2466D4A8A87E

Q37901520-333FF756-7F5F-4CB8-91D3-8694A34DA690

Q37901520-3700A2DB-9BCF-4FF0-BFFA-FF217EE5B6CC

P304

Q37901520-FA08B923-1099-41F4-9FA3-E1FF983C2B27

P31

Q37901520-AAD263FA-175A-486A-932F-F45660F94F58

P356

Q37901520-7A4C2A4C-1DC5-42B7-8587-0B1FA88FA6FB

P433

Q37901520-A71C4FBF-31EA-4746-A687-1A18005F6FB2

P478

Q37901520-6F15B881-5298-4E8E-9320-7732FAC22D3B

P50

Q37901520-7DCF0EE4-A666-47A7-9C4B-9E3F849EBEDB

P577

Q37901520-EE3A6CDD-51D7-462B-B83E-E74C0AF12543

P5875

Q37901520-581DD702-1128-4A8F-8A58-E062174A9D3A

P698

Q37901520-2A38E809-1BF1-4014-BCFD-5AEBB5763BAA

P932

Q37901520-44217271-A633-4680-BD41-1CD27C11FE9B

P356

J.1365-2249.2011.04443.X

P1433

Clinical and Experimental Immunology

P1476

Bringing immunoglobulin knowledge up to date: how should we treat today?

@en

P2093

B Grimbacher

http://www.w3.org/2001/XMLSchema#string

D Guzman

http://www.w3.org/2001/XMLSchema#string

J van der Heijden

http://www.w3.org/2001/XMLSchema#string

S Misbah

http://www.w3.org/2001/XMLSchema#string

T Kuijpers

http://www.w3.org/2001/XMLSchema#string

P2860

Global variation in copy number in the human genome

Prospective study of the aetiology and outcome of pneumonia in the community

The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.

Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura.

Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency

Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans.

Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings.

Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.

Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B.

The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia.

P304

16-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2249.2011.04443.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

166

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51495451

http://www.w3.org/2001/XMLSchema#string

P698

21762127

http://www.w3.org/2001/XMLSchema#string

P932

3193915

http://www.w3.org/2001/XMLSchema#string